Fluoxetine versus placebo in advanced cancer outpatients: A double-blinded trial of the Hoosier Oncology Group

Michael J. Fisch, Patrick Loehrer, Jean Kristeller, Steven Passik, Sin Ho Jung, Jianzhao Shen, Matthew A. Arquette, Mary J. Brames, Lawrence Einhorn

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Purpose: To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey. Patients and Methods: One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine (20 mg daily) or placebo for 12 weeks. Patients were screened for at least minimal depressive symptoms and assessed every 3 to 6 weeks for QOL and depression. Patients with recent exposure to antidepressants were excluded. Results: The groups were comparable at baseline in terms of age, sex, disease distribution, performance status, and level of depressive symptoms. One hundred twenty-nine patients (79%) completed at least one follow-up assessment. Analysis using generalized estimating equation modeling revealed that patients treated with fluoxetine exhibited a significant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General, compared with patients given placebo (P = .01). Specifically, the level of depressive symptoms expressed was lower in patients treated with fluoxetine (P = .0005), and the subgroup of patients showing higher levels of depressive symptoms on the two-question screening survey were the most likely to benefit from treatment. Conclusion: In this mix of patients with advanced cancer who had symptoms of depression as determined by a two-question bedside survey, use of fluoxetine was well tolerated, overall QOL was improved, and depressive symptoms were reduced.

Original languageEnglish
Pages (from-to)1937-1943
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - May 15 2003

Fingerprint

Fluoxetine
Outpatients
Placebos
Depression
Neoplasms
Quality of Life
Sex Distribution
Antidepressive Agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fluoxetine versus placebo in advanced cancer outpatients : A double-blinded trial of the Hoosier Oncology Group. / Fisch, Michael J.; Loehrer, Patrick; Kristeller, Jean; Passik, Steven; Jung, Sin Ho; Shen, Jianzhao; Arquette, Matthew A.; Brames, Mary J.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 21, No. 10, 15.05.2003, p. 1937-1943.

Research output: Contribution to journalArticle

Fisch, Michael J. ; Loehrer, Patrick ; Kristeller, Jean ; Passik, Steven ; Jung, Sin Ho ; Shen, Jianzhao ; Arquette, Matthew A. ; Brames, Mary J. ; Einhorn, Lawrence. / Fluoxetine versus placebo in advanced cancer outpatients : A double-blinded trial of the Hoosier Oncology Group. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 10. pp. 1937-1943.
@article{eee0699b2e654b459ee40d42c55767df,
title = "Fluoxetine versus placebo in advanced cancer outpatients: A double-blinded trial of the Hoosier Oncology Group",
abstract = "Purpose: To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey. Patients and Methods: One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine (20 mg daily) or placebo for 12 weeks. Patients were screened for at least minimal depressive symptoms and assessed every 3 to 6 weeks for QOL and depression. Patients with recent exposure to antidepressants were excluded. Results: The groups were comparable at baseline in terms of age, sex, disease distribution, performance status, and level of depressive symptoms. One hundred twenty-nine patients (79{\%}) completed at least one follow-up assessment. Analysis using generalized estimating equation modeling revealed that patients treated with fluoxetine exhibited a significant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General, compared with patients given placebo (P = .01). Specifically, the level of depressive symptoms expressed was lower in patients treated with fluoxetine (P = .0005), and the subgroup of patients showing higher levels of depressive symptoms on the two-question screening survey were the most likely to benefit from treatment. Conclusion: In this mix of patients with advanced cancer who had symptoms of depression as determined by a two-question bedside survey, use of fluoxetine was well tolerated, overall QOL was improved, and depressive symptoms were reduced.",
author = "Fisch, {Michael J.} and Patrick Loehrer and Jean Kristeller and Steven Passik and Jung, {Sin Ho} and Jianzhao Shen and Arquette, {Matthew A.} and Brames, {Mary J.} and Lawrence Einhorn",
year = "2003",
month = "5",
day = "15",
doi = "10.1200/JCO.2003.08.025",
language = "English",
volume = "21",
pages = "1937--1943",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Fluoxetine versus placebo in advanced cancer outpatients

T2 - A double-blinded trial of the Hoosier Oncology Group

AU - Fisch, Michael J.

AU - Loehrer, Patrick

AU - Kristeller, Jean

AU - Passik, Steven

AU - Jung, Sin Ho

AU - Shen, Jianzhao

AU - Arquette, Matthew A.

AU - Brames, Mary J.

AU - Einhorn, Lawrence

PY - 2003/5/15

Y1 - 2003/5/15

N2 - Purpose: To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey. Patients and Methods: One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine (20 mg daily) or placebo for 12 weeks. Patients were screened for at least minimal depressive symptoms and assessed every 3 to 6 weeks for QOL and depression. Patients with recent exposure to antidepressants were excluded. Results: The groups were comparable at baseline in terms of age, sex, disease distribution, performance status, and level of depressive symptoms. One hundred twenty-nine patients (79%) completed at least one follow-up assessment. Analysis using generalized estimating equation modeling revealed that patients treated with fluoxetine exhibited a significant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General, compared with patients given placebo (P = .01). Specifically, the level of depressive symptoms expressed was lower in patients treated with fluoxetine (P = .0005), and the subgroup of patients showing higher levels of depressive symptoms on the two-question screening survey were the most likely to benefit from treatment. Conclusion: In this mix of patients with advanced cancer who had symptoms of depression as determined by a two-question bedside survey, use of fluoxetine was well tolerated, overall QOL was improved, and depressive symptoms were reduced.

AB - Purpose: To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey. Patients and Methods: One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine (20 mg daily) or placebo for 12 weeks. Patients were screened for at least minimal depressive symptoms and assessed every 3 to 6 weeks for QOL and depression. Patients with recent exposure to antidepressants were excluded. Results: The groups were comparable at baseline in terms of age, sex, disease distribution, performance status, and level of depressive symptoms. One hundred twenty-nine patients (79%) completed at least one follow-up assessment. Analysis using generalized estimating equation modeling revealed that patients treated with fluoxetine exhibited a significant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General, compared with patients given placebo (P = .01). Specifically, the level of depressive symptoms expressed was lower in patients treated with fluoxetine (P = .0005), and the subgroup of patients showing higher levels of depressive symptoms on the two-question screening survey were the most likely to benefit from treatment. Conclusion: In this mix of patients with advanced cancer who had symptoms of depression as determined by a two-question bedside survey, use of fluoxetine was well tolerated, overall QOL was improved, and depressive symptoms were reduced.

UR - http://www.scopus.com/inward/record.url?scp=0037674065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037674065&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.025

DO - 10.1200/JCO.2003.08.025

M3 - Article

C2 - 12743146

AN - SCOPUS:0037674065

VL - 21

SP - 1937

EP - 1943

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -